NCT05853913

Brief Summary

Dementia is a leading cause of death in the United States among aging adults. Brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise decreases Alzheimer's Disease (AD) risk, in part, through changes in brain structure and function. However, there is limited data available on how exercise impacts brain insulin resistance in aging. This study will test the effect of acute exercise on brain insulin sensitivity in middle-aged to older adults. The study will also examine cognition and cardiometabolic health in relation to brain insulin sensitivity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2023

Typical duration for not_applicable

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2023

Completed
22 days until next milestone

First Posted

Study publicly available on registry

May 11, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

May 11, 2023

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2025

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 25, 2025

Completed
Last Updated

November 21, 2025

Status Verified

November 1, 2025

Enrollment Period

1.9 years

First QC Date

April 19, 2023

Last Update Submit

November 18, 2025

Conditions

Keywords

Exercise

Outcome Measures

Primary Outcomes (1)

  • Brain insulin sensitivity

    MRI arterial spin labeling, cerebral blood flow

    Change from baseline to exercise; about 1 week apart

Secondary Outcomes (5)

  • Cognition

    Change from baseline to exercise; about 1 week apart

  • Blood Glucose

    Change from baseline to exercise; about 1 week apart

  • Blood Free Fatty Acids

    Change from baseline to exercise; about 1 week apart

  • Carbohydrate Use

    Change from baseline to exercise; about 1 week apart

  • Systolic and Diastolic Blood Pressure

    Change from baseline to exercise; about 1 week apart

Study Arms (2)

Rest

NO INTERVENTION

Individuals will rest for about 1 hour in the seated position to mimic time exercising.

Exercise

EXPERIMENTAL

Individuals will exercise for at medium to hard intensity for 1 hour.

Behavioral: Exercise

Interventions

ExerciseBEHAVIORAL

Exercise will be walking/jogging at a medium to hard intensity for 1 hour.

Exercise

Eligibility Criteria

Age40 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female \>/=40 and \</=80 years old.
  • Has a body mass index \>/=25 and \</=45 kg/m2.
  • Physical Activity (\<150 min of moderate/high intensity exercise per week)

You may not qualify if:

  • Subjects who have not been weight stable (\>2 kg weight change in past 3 months)
  • Subjects who are smokers or who have quit smoking \<1 years ago
  • Subjects with abnormal estimated glomerular filtration rate (eGFR).
  • Hypertriglyceridemic (\>400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects
  • Hypertensive (\>160/100 mmHg)
  • Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures or impact subject safety.
  • Pregnant (as evidenced by positive urine pregnancy test) or nursing women
  • Subjects with contraindications to participation in an exercise
  • Current Pregnancy
  • Currently taking active weight suppression medication (e.g. phentermine, orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzphetamine, diethylpropion, phendimetrazine)
  • Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).
  • Known contraindications for MRI imaging

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Institute for Food, Nutrition, and Health

New Brunswick, New Jersey, 08901, United States

Location

Robert Wood Johnson University Hospital Clinical Research Center

New Brunswick, New Jersey, 08901, United States

Location

Rutgers University Loree Gymnasium

New Brunswick, New Jersey, 08901, United States

Location

Center for Advanced Human Brain Imaging Research

Piscataway, New Jersey, 08854, United States

Location

MeSH Terms

Conditions

ObesityInsulin ResistanceMotor Activity

Interventions

Exercise

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesBehavior

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Steven K Malin, PhD

    Rutgers University - New Brunswick

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Individuals will perform both rest and exercise conditions.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

April 19, 2023

First Posted

May 11, 2023

Study Start

May 11, 2023

Primary Completion

March 20, 2025

Study Completion

March 25, 2025

Last Updated

November 21, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations